Morphic Therapeutic is leading the development of a new generation of oral integrin drugs, informed by decades of world-leading expertise and a unique integrin discovery platform. Morphic believes oral drugs targeting the integrin protein family can transform the treatment paradigm for patients suffering from serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Nov 15, 2022 at 10:55 AM GMT
Sep 8, 2022 at 10:25 AM EDT
Jun 9, 2022 at 2:00 PM EDT
Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis
Nov 22, 2022
Nov 09, 2022
Nov 02, 2022